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Abstract We aimed to develop a user-centered, web-
based, decision support tool for breast cancer risk assess-
ment and personalized risk management. Using a novel
model choice algorithm, iPrevent selects one of two
validated breast cancer risk estimation models (IBIS or
BOADICEA), based on risk factor data entered by the user.
Resulting risk estimates are presented in simple language
and graphic formats for easy comprehension. iPrevent
then presents risk-adapted, evidence-based, guideline-en-
dorsed management options. Development was an iterative
process with regular feedback from multidisciplinary
experts and consumers. To verify iPrevent, risk factor
data for 127 cases derived from the Australian Breast
Cancer Family Study were entered into iPrevent, IBIS
(v7.02), and BOADICEA (v3.0). Consistency of the model
chosen by iPrevent (i.e., IBIS or BOADICEA) with the
programmed iPrevent model choice algorithm was
assessed. Estimated breast cancer risks from iPrevent
were compared with those attained directly from the cho-
sen risk assessment model (IBIS or BOADICEA). Risk
management interventions displayed by iPrevent were
assessed for appropriateness. Risk estimation model choice
was 100 % consistent with the programmed iPrevent
logic. Discrepant 10-year and residual lifetime risk esti-
mates of[1 % were found for 1 and 4 cases, respectively,Electronic supplementary material The online version of this
article (doi:10.1007/s10549-016-3726-y) contains supplementary
material, which is available to authorized users.
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none was clinically significant (maximal variation 1.4 %).
Risk management interventions suggested by iPrevent
were 100 % appropriate. iPrevent successfully integrates
the IBIS and BOADICEA risk assessment models into a
decision support tool that provides evidence-based, risk-
adapted risk management advice. This may help to facili-
tate precision breast cancer prevention discussions between
women and their healthcare providers.
Keywords Breast cancer  Risk  Decision support 
BRCA1  Chemoprevention
Introduction
A woman’s risk of breast cancer is due to a complex inter-
play between genetic, environmental, and lifestyle factors
[1]. Major risk factors include having a family history of the
disease and/or a mutation in a breast cancer predisposition
gene, history of therapeutic chest irradiation, and history of a
breast biopsy showing atypical hyperplasia or lobular car-
cinoma in situ (LCIS). Other risk factors include early
menarche, late menopause, prolonged use of combined
hormone replacement therapy, obesity, and alcohol con-
sumption, while child bearing and breast feeding are pro-
tective. With medical practice moving toward precision
prevention [2], it is now possible to estimate the risk of breast
cancer for an individual woman. Knowledge of an individ-
ual’s breast cancer risk facilitates use of evidence-based
management strategies [3] appropriate for that risk level, and
allows calculation of the absolute benefit, in terms of risk
reduction, for each strategy. Breast cancer risk management
strategies include risk-reducing bilateral mastectomy [4],
premenopausal bilateral salpingo-oophorectomy [5], medi-
cal prevention with selective estrogen receptor modulators
or aromatase inhibitors [6, 7], breast cancer screening [3, 8],
and lifestyle modifications such as maintaining a healthy
weight and reducing alcohol intake [9].
Several mathematical models have been developed to
estimate breast cancer risk [10]. Some are designed pri-
marily for use by experienced clinicians or geneticists,
others are aimed at specific risk groups, such as those at
high risk [11]. To our knowledge, none integrates person-
alized, absolute risk estimates with comprehensive, risk-
adapted, management options including personalized
absolute risk reduction estimates for each option. Two
well-validated breast cancer risk estimation models are the
International Breast Cancer Intervention Study (IBIS)
model [12] and the Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm (BOADICEA)
model [13, 14]. These models have been validated in a
prospective cohort showing good discrimination and
accuracy [15, 16].
The IBIS and the BOADICEA tools vary in the extent of
risk factor data they use to estimate risk. While both use
family history data, IBIS limits family history input to first-
and second-degree relatives or third-degree female rela-
tives with breast or ovarian cancer only. BOADICEA also
incorporates breast cancer pathology characteristics, family
history of prostate or pancreatic cancer as well as the input
of data from relatives of any degree of relatedness. IBIS
also uses other risk factor data, including body mass index,
reproductive factors, and personal history of high-risk
breast lesions such as atypical hyperplasia and LCIS.
BOADICEA does not currently consider these factors.
Neither model integrates risk-adapted management infor-
mation in its output.
Clinical management decisions in medicine, and
oncology in particular, are becoming more data dependent
but for many decisions the relative benefits and harms are
uncertain, suggesting a need for greater shared decision
making. While scientific advances enable a more tailored
approach to patients, this requires greater specialist
knowledge which may not be widely available. Indeed,
qualitative studies undertaken to inform the development
of iPrevent, revealed that healthcare providers often have
difficulty accurately and easily assessing and communi-
cating breast cancer risk and the absolute benefits and
disadvantages of risk management interventions [17]. They
seek a tool that is evidence based, accessible, provides
10-year and residual lifetime risk estimates, and displays
absolute rather than relative risks and risk reductions in
multiple formats to account for patients with differing
information needs [17].
We aimed to develop and verify a tool for healthcare
providers and women to use collaboratively, that integrates
accurate and personalized breast cancer risk assessment
(using the IBIS and BOADICEA models) and that displays
risk-adapted, personalized, risk management information.
Methods
A user-centered approach was employed with all aspects of
iPrevent design. We assessed user needs by conducting
focus groups with primary care doctors and nurses, breast
surgeons, consumers, breast cancer screening program staff,
and clinicians in genetics clinics [17, 18]. This identified
potential barriers to implementation of the tool in everyday
clinical practice, as well as the concerns of prospective users.
Where possible, these issues were addressed in the software
design phase. During iPrevent development, the wording,
format, and layout of the output pages was reviewed and
optimized by a prototype design committee comprising: an
academic general practitioner (with a special interest in the
development of clinical decision support tools for cancer), a
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breast surgeon, a clinical geneticist, a psycho-oncologist
(with a special interest in risk presentation), an epidemiol-
ogist, two consumer advocates, two medical oncologists
(with a special interest in breast cancer risk management),
and the software developers. The aim of this inclusive
approach to the iPrevent design was to maximize clinical
utility by building a tool that satisfies user requirements.
iPrevent starts with a disclaimer page outlining the
limitations of its use. The software comprises three main
modules: (i) data input, (ii) risk evaluation, and (iii) results
output including personalized risk estimation and risk
management options.
Data input
The data input module is presented as a series of pages with
related questions through which the user can easily navigate
backwards and forwards (Fig. 1). iPrevent requires the user
to enter the data required by either tool, where available, but
reduces the data input burden for family history when com-
pared to BOADICEA. The program minimizes the number of
questions required to be completed by hiding those questions
that become unnecessary, for example, detailed family his-
tory data are not collected for users who answer a screening
question by stating that they have no family history of breast,
ovarian, pancreatic, or prostate cancer. Conversely, some
questions must always be answered as they are necessary for
accurate risk estimation by IBIS and/or BOADICEA, e.g.,
BOADICEA requires the year of birth and age at diagnosis of
relatives affected by cancer.
At the conclusion of the data input stage, iPrevent
displays a plain English summary of the entered family
history. Should the user identify errors at this time, she can
navigate back to the family history pages and correct data.
Risk evaluation
The iPrevent model choice algorithm (Fig. 2) was adap-
ted from Amir et al. [10] and selects the risk assessment
model, IBIS, or BOADICEA, which will be used to cal-
culate the individualized risk estimate for each user. The
risk factor data entered into iPrevent are used to interface
with the relevant breast cancer risk estimation model, via
the Internet. Interfacing with BOADICEA is done through
the online version of the tool (version 3.0) hosted at
Cambridge, UK [19]. Interfacing with IBIS (version 7.02)
is achieved via the Harvard Risk Service.
Results output: risk estimation
The results module is designed to provide a risk output
style that is the same regardless of the background model
used to calculate the risk.
The 10-year and residual lifetime breast cancer risks, as
estimated by either IBIS or BOADICEA, are presented to
the woman along with the age-matched population 10-year
and residual lifetime risks. While IBIS provides age-mat-
ched population risks, the online BOADICEA tool cur-
rently provides age-matched country-specific population
risks in graphical form only. We used population-based
data from Australian Cancer Incidence and Mortality
(ACIM), an Australian dataset for 2009, to estimate the
age-matched population breast cancer risks [20]. iPrevent
displays this population risk estimate when BOADICEA is
the nominated risk estimation model.
iPrevent initially conveys a qualitative outline of risk
e.g., ‘‘Your risk of developing breast cancer is substantially
increased for a woman of your age. However this does not
necessarily mean that you will develop breast cancer.’’ It
then allows a woman, with the support of her healthcare
provider, to access the detailed, quantitative risk estimates
only if they choose to. Users may elect whether to view
any, or all of the specific risk estimation formats, i.e., text,
pictograms, and/or graphs as shown in Fig. 3a and b.
Figure 3c shows the comparable risk estimate outputs
derived directly for IBIS and BOADICEA.
Results output: risk management
iPrevent presents risk-adapted management options based
on Australian guidelines [3]. Using the estimated residual
lifetime risk, women are assigned a risk category: average
risk (i.e.,\1.5 times population risk), moderately increased
risk (i.e., 1.5–3 times population risk), or high risk (i.e.,[3
times population risk) [3]. Based on the assigned category,
relevant risk management options are presented to the user
(Table 1).
The risk management options appear as a list, tailored to
the woman’s risk category and her input data. The user
may choose to click on any or all options in the list to view
more details, or she may choose to skip these details
altogether.
When details of each risk-reducing option are viewed,
estimates are provided of the absolute risk reduction,
specific to that woman, for the viewed option (Fig. 3d).
Such risk reduction estimates are not available from IBIS
and BOADICEA directly. Estimates of the magnitude of
relative risk reduction for each option are derived from
published data [4, 5, 21–24]. This relative risk reduction is
applied to the individual user’s estimated absolute 10-year
and residual lifetime breast cancer risk, to give a person-
alized estimate of the absolute risk reduction for each
option, presented in the same range of formats. Information
on possible disadvantages/side-effects of each option is
also provided. In addition, there are links specific for
Breast Cancer Res Treat (2016) 156:171–182 173
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healthcare providers, e.g., tips for safe prescribing of risk-
reducing medication.
Results output: data presentation
An important element in the design of iPrevent is the
presentation of breast cancer risk estimates, risk reduction,
and possible side-effects estimates for each management
option, in a way that is easily understood by women of
varying levels of education and literacy, and for healthcare
providers who are not experts in risk presentation. There-
fore, all breast cancer risks and risk reductions are pre-
sented as words, percentages, a visual scale or pictogram
(icon arrays with 1000 women), and graphs. This use of
multiple formats to display risk aims to reduce bias in how
the numbers may be perceived, while also increasing
understanding [25, 26].
With the same aim of maximizing comprehension, the
language used in all iPrevent output pages was aimed at a
Flesch–Kincaid reading grade level of eight (the estimated
number of years of education required for comprehension)
[27]. iPrevent is designed for use in conjunction with a
healthcare provider who can bridge any gaps in
understanding.
Future proofing
Updates to IBIS and BOADICEA are expected to occur
over time, for example to include mammographic density
and single nucleotide polymorphisms (SNPs—variations in
Fig. 1 Screenshot of the
iPrevent reproductive history
data entry page
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the smallest portions of DNA) data into the risk estimation.
These updates can readily be integrated into iPrevent
provided that they do not fundamentally alter the way in
which iPrevent interacts with the risk assessment models.
The interface with the two models is separated to ensure
ease of updating just one interface if required. While many
users expressed an interest in the development of iPrevent
as an app for their smart phone or tablet, this would limit
the ability of the developers to force updates, preventing
users from access to an outdated version in the future.
Verification
Verification relates to ensuring that the computerized
model and its implementation are correct, while validation
ensures sufficient accuracy of that model in a clinical
context [28]. The IBIS and BOADICEA models have
already been prospectively validated for calibration and
discriminatory accuracy of breast cancer risk estimates
[16]. The main objective of verification was to determine
the accuracy of the software system, including detecting
coding errors and verifying the correct risk estimation
model selection according to the iPrevent algorithm [29].
While iPrevent is, to some extent, dependant on the
validity of the data derived from IBIS and BOADICEA, its
operational validity [30], such that clinically appropriate
outputs are presented, was also confirmed using a popula-
tion-based dataset.
iPrevent was tested using risk factor data on 127 cases
derived from women with no personal history of breast
cancer, enrolled in the Australian Breast Cancer Family
Study (ABCFS) [31], a population-based case–control
breast cancer family study. The ABCFS was approved by
the Human Research Ethics Committees of the University
of Melbourne, the Cancer Council Victoria, and Cancer
Council NSW, and all participants provided written
informed consent. The cases were selected for inclusion
because they had sufficient risk factor data for the models
across the range of breast cancer risks that would be
expected to be seen in a variety of clinical settings. The
data were manually entered into each of IBIS (v7.02) and
BOADICEA (v3.0) models, and iPrevent independently,
and the resulting 10-year and residual lifetime risk esti-
mates recorded and manually categorized as average,
moderate, or high risk. Whether the correct (IBIS or
BOADICEA) model, according to the iPrevent algorithm
(Fig. 2) was chosen by iPrevent was also recorded. The
numbers of cases at each branch of the algorithm was also
noted (Fig. 2) to ensure that a broad variety of clinical
scenarios were tested. Estimated 10-year and residual
Personal history of 
LCIS or AH?
Personal or family 
history of BRCA 
mutaon?
Family history of 
breast/ovarian 
cancer?
Family history of 
breast cancer only?
First degree 
relaves only?
Select IBIS Select BOADICEA
No
No
Yes
Yes
n=68
n=107
n=55
n=41
n=127
Yes
n=39
n=14
No
n=22
No
No
n=13
Yes
n=20
n=19
Yes
LCIS = Lobular carcinoma in situ 
AH = Atypical hyperplasia
Fig. 2 iPrevent algorithm for the choice of risk estimation model and verification
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Your Risk Over the Rest of Your Life
Your risk of developing breast cancer over the rest of your life is 69.6%.This means 696 
out of 1000 women your age, with the same risk of breast cancer as you, will develop 
breast cancer at some time in their life. 
The risk for an average woman of your age is 10.3%. This means 103 out of 1000 
women of your age, at average risk in the general population, will develop breast cancer 
at some time in their life. 
(a)
(b)
Fig. 3 a iPrevent
Screenshot—text and pictogram
of personalized risk and
population risk for a 36-year-old
BRCA1 mutation carrier.
b iPrevent Screenshot—graph
of personalized risk and
population risk for a 36-year-old
BRCA1 mutation carrier.
c Selected output derived
directly from IBIS and
BOADICEA for the same
36-year-old BRCA1 mutation
carrier for comparison.
d iPrevent Screenshot—text
and pictogram of risk reduction
from bilateral prophylactic
mastectomy for a 36-year-old
BRCA1 mutation carrier
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lifetime breast cancer risks from iPrevent were compared
with those attained directly from the chosen model. Vari-
ations of greater than 1 % were considered discrepant. The
breast cancer risk management options provided by
iPrevent for these 127 cases were assessed for consistency
with national guideline recommendations [3], and the
absolute risk reductions for each presented risk manage-
ment option were manually calculated and compared with
those calculated by iPrevent. The output pages presented
by iPrevent for each case were compared to the data
entered, as these data were used to present tailored rec-
ommendations for lifestyle modifications such as reducing
weight (if overweight) and reducing alcohol intake (if
consuming greater than national recommendations).
Results
Testing and verification
In the ABCFS derived dataset, iPrevent used BOADICEA
for 75 (59 %) of the 127 cases, including 36, 31, and 8
cases at high, moderate, and average risk, respectively. For
the remaining cases where IBIS was used, 21, 12, and 19
BOADICEA – Breast Cancer Risk Output
Breast cancer risks (Graph)
Note: BOADICEA Ovarian cancer risk estimate omitted here.
IBIS – Breast Cancer Risk Output
79.5%
63.6%
47.7%
31.8%
15.9%
0.0%
36 41 46 51 56 61 66 71 76 85
Age Breast cancer risks (Percent)
37 1.9
38 3.8
39 5.9
40 8.0
41 10.1
45 19.8
46 22.4
50 32.5
55 43.7
60 52.8
65 60.1
70 65.4
75 68.8
80 71.1
(c)
Fig. 3 continued
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were at high, moderate, and average risk, respectively. The
correct risk assessment model, according to the iPrevent
algorithm (Fig. 2), was chosen in all 127 cases (100 %).
Discrepant 10-year and residual lifetime risk estimates of
[1 % were found for 1 (1 %) and 4 (3 %) cases, respec-
tively, when iPrevent results were compared with the
background risk model (IBIS or BOADICEA) used
(Table 2).
All 4 of these cases (for 1 case both 10-year and lifetime
risks were discrepant), involved women at population risk
of breast cancer, with no personal or family history of
breast cancer or cancer predisposition genes (BRCA1 and
BRCA2). In order to minimize the data entry required,
iPrevent does not ask users for data on unaffected rela-
tives in these low risk women as the results are not
expected to change recommendations. This can lead to
Reduction in your risk over your lifetime
Risk reducing mastectomy will reduce your risk of developing invasive breast cancer 
over the rest of your life from 69.6% to 7.0%. 
Over the same time, the breast cancer risk for an average woman of your age is 10.3%. 
This means that if 1000 women with the same risk of breast cancer as you all had the 
operation, 70 would get breast cancer over the rest of their lives. However if none of the 
1000 women had the operation 696 would get breast cancer. So by having the operation 
breast cancer would have been prevented in 626 women. 
(d)
Fig. 3 continued
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very minor, and clinically insignificant variations in the
presented estimate for 10-year or residual lifetime breast
cancer risk, but greatly enhances ease of use of iPrevent.
All differences noted were considered to be clinically
insignificant and none led to a change in the woman’s
breast cancer risk category nor to the risk management
options presented by iPrevent.
iPrevent provided the appropriate risk management
options including lifestyle changes, according to Australian
guidelines [3] in all 127 (100 %) cases. The correct abso-
lute risk reduction was also shown in 100 % of cases.
Discussion
We developed iPrevent, a web-based decision support
tool that integrates two validated risk assessment models to
estimate a woman’s personal breast cancer risk and then
facilitates discussions between women and their health care
providers about evidence-based measures to manage that
risk, by providing information tailored to each woman. We
took a user-centered approach with the aim of meeting the
end user’s needs as identified in our previous research [17,
18]. We verified the coding of iPrevent using a popula-
tion-based dataset to ensure the breast cancer risk estimates
and risk management information presented were derived
correctly according to our algorithm (Fig. 2; Table 1) and
thus clinically appropriate. We defined an arbitrary cut-off
for the verification of risk estimates of \1 % from the
expected breast cancer risk (derived directly from the
validated IBIS or BOADICEA model) as an accept-
able variation. This definition is strict and much wider
variation is likely to be acceptable in a clinical context. A
variation of 1 % will only rarely change the risk category
(Table 1) that a woman is assigned to and will not sub-
stantially alter the risk reduction estimates for any given
risk management option. For example, for risk-reducing
medication with tamoxifen a variation of 1 % in risk esti-
mate results in a variation of only 0.67 % in the absolute
risk reduction estimate, which is unlikely to influence
clinical decision making.
Future features
iPrevent is intended to be a dynamic tool, designed to
allow for the incorporation of updated data on breast cancer
risk assessment and risk management without major coding
changes. Anticipated future changes to breast cancer risk
assessment include the incorporation of elements known to
affect breast cancer risk but not currently well defined in
Table 1 iPrevent risk management options by breast cancer risk category
Risk category Category risk
definition
Lifestyle
modificationa
Radiological
screeningb
Risk-reducing
medicationc
Risk-reducing
surgeryd,e
Average \1.5 times population risk All women Biennial mammogramf No No
Moderately increased 1.5–3 times population risk All women Annual mammogram Yes No
High [3 times population risk All women Annual mammogram and breast MRIg Yes Yes
a Includes regular exercise, not smoking, maintaining a healthy weight, and minimizing alcohol intake
b Does not reduce risk of breast cancer but may help detect cancer earlier
c Includes tamoxifen for premenopausal women, and raloxifene, anastrazole, exemestane, or tamoxifen for postmenopausal women
d Includes risk-reducing mastectomy and premenopausal risk-reducing salpingo-oophorectomy
e The risk reduction with medication and surgery may not be additive, for example, those who have undergone salpingo-oophorectomy may not
benefit further from medication such as tamoxifen
f From 50 to 74 years of age
g MRI (magnetic resonance imaging) only in women aged 18–50 years
Table 2 Discrepancies in breast cancer risk estimation between iPrevent and the chosen risk estimation model
Model selected iPrevent risk estimates (%) IBIS or BOADICEA model risk estimates (%) Difference between iPrevent and model
used (%)
10-year Residual lifetime 10-year Residual lifetime 10-year Residual lifetime
IBIS 3.1 14.3 2.8 13.2 0.3 1.1
IBIS 4.7 8.2 3.9 6.8 0.8 1.4
IBIS 4.2 14.3 2.9 10.3 1.3 4
IBIS 2.7 9.5 2.3 8.1 0.4 1.4
Discrepancies were seen in 4 of 127 cases tested
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terms of their interaction with family history and other
factors modeled by IBIS and BOADICEA. For example,
mammographic density is an important risk factor for
breast cancer [32], and the IBIS and BOADICEA devel-
opers are currently working on its inclusion in these
models. Similarly, SNPs in multiple genes affect breast
cancer risk [33], and it is expected these will be included in
these models in the future.
Integration of the iPrevent breast cancer risk with per-
sonally controlled health record (PCHR) platforms [34], is
also an ideal future use, allowing the risk calculation to be
updated over time, with respect to changing circumstances.
While the risk reduction estimates programmed into
iPrevent are based on the best current data, refinements are
likely to occur over time. For example, iPrevent currently
applies a 50 % relative risk reduction for breast cancer with
risk-reducing salpingo-oophorectomy before 45 years of age
[23, 35]. Modeling studies [11] have investigated this
research question, but greater data are required for individ-
ualization of the risk reduction estimates. It is likely that
when more prospective data are available [36], a more
accurate age-adapted risk reduction will be known and hence
able to be incorporated into iPrevent.
Ultimately, it is envisaged that iPrevent will enable
healthcare providers to assess and manage a woman’s
breast cancer risk easily and routinely as part of a pre-
vention consultation. The current uptake of risk-reducing
interventions, even among women at highest risk, is low
[37]. iPrevent will empower women to know their breast
cancer risk and understand the pros and cons of various
interventions. It will provide users with accurate and per-
sonalized risk assessment and risk management informa-
tion with the intention of improving decision making
regarding risk management options.
iPrevent may be applied to women across the spectrum
of breast cancer risk, in a variety of specialist and primary
care clinical settings, to provide an evidence-based
approach to breast cancer risk assessment and management
and to optimize shared decision making between patient
and healthcare provider.
IBIS and BOADICEA are excellent breast cancer risk
assessment models that have been well validated.
iPrevent provides potential advantages over either model
alone, as it automatically uses the most appropriate of these
models depending on the data inputted. In addition, the
interface has been designed to be easier for women and
inexperienced clinicians to use compared with the data
input interfaces for IBIS and BOADICEA. Perhaps, the
most important distinction though is that IBIS and BOA-
DICEA provide only breast cancer risk information,
whereas iPrevent also provides evidence-based risk
management options tailored to the woman’s estimated risk
level. Furthermore, iPrevent displays the absolute risk
reduction that can be achieved with each risk management
option for each individual woman, providing an excellent
platform for informed decision making.
The aim of this project was to develop a personalized,
evidence-based, risk assessment, and risk management
decision support tool for breast cancer. The results of our
verification study show that this goal has been achieved.
We are currently undertaking a large pilot study of
iPrevent with 70 women and 20 clinicians across three
different clinical settings (primary care, breast surgical
clinics, and genetics clinics). The aims of this piloting work
is to (i) assess the acceptability of the content, layout, and
presentation of iPrevent, and (ii) identify any issues with
usability and potential barriers to implementation which
can then be addressed in future iterations of the tool. We
believe the user satisfaction with iPrevent will be a key
driver to its widespread use and ultimately better person-
alized breast cancer risk awareness for all women. It is
hoped to make iPrevent widely and freely available on the
web to all healthcare providers in the near future, once
piloting is complete.
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